Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: CNS Drugs. 2019 Oct;33(10):1001–1030. doi: 10.1007/s40263-019-00664-w

Fig. 1.

Fig. 1

The endocannabinoid system, including the synthesis and degradation enzymes (FAAH, MAGL) of endocannabinoids (AEA and 2-AG), cannabinoid receptors (CB1 and CB2), anandamide transporter (FABPs), and the five major therapeutic targets (CB1, CB2, FAAH, MAGL, FABPS). AEA anandamide, DAG diacylglycerol, FAAH fatty acid amide hydrolase, FABPs fatty acid-binding proteins, MAGL monoacylglycerol lipase, NAPE-PLD N-arachidonoyl phosphatidylethanolamine-phospholipase D, PE phosphatidylethanolamine, 2-AG 2-arachidonoylglycerol

OSZAR »